Volume 11, Issue 3, Pages (March 2010)

Slides:

Advertisements

Similar presentations

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast.

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Fever of unknown origin and cancer: a population-based study

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Markers and management of germ-cell tumours of the testes

Volume 356, Issue 9239, Pages (October 2000)

Volume 6, Issue 7, Pages (July 2005)

Volume 18, Issue 6, Pages (June 2017)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 18, Issue 7, Pages (July 2017)

Volume 11, Issue 4, Pages (April 2012)

Volume 3, Issue 3, Pages (March 2016)

Volume 15, Issue 6, Pages (May 2014)

Volume 19, Issue 2, Pages (February 2018)

Volume 5, Issue 4, Pages (April 2006)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 377, Issue 9783, Pages (June 2011)

Volume 9, Issue 5, Pages (May 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 13, Issue 3, Pages (March 2012)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 2, Pages (February 2014)

Volume 1, Issue 3, Pages (August 2014)

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 14, Issue 7, Pages (June 2013)

Volume 12, Issue 12, Pages (November 2011)

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 9, Issue 10, Pages (October 2008)

Antibiotic prescription strategies for acute sore throat: a prospective observational cohort study Prof Paul Little, FMedSci, Beth Stuart, Prof F D Richard.

Volume 14, Issue 8, Pages (July 2013)

Volume 18, Issue 7, Pages (July 2017)

Volume 14, Issue 8, Pages (July 2013)

Volume 15, Issue 6, Pages (May 2014)

Volume 16, Issue 6, Pages (June 2015)

HIV myths should not be resuscitated

Volume 4, Issue 6, Pages (June 2017)

Volume 18, Issue 3, Pages (March 2017)

Volume 6, Issue 6, Pages (June 2005)

Volume 14, Issue 6, Pages (May 2013)

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 18, Issue 3, Pages (March 2017)

Volume 373, Issue 9676, Pages (May 2009)

Volume 9, Issue 4, Pages (April 2008)

Volume 381, Issue 9880, Pages (May 2013)

Volume 5, Issue 4, Pages (April 2018)

Volume 16, Issue 8, Pages (August 2015)

Volume 14, Issue 8, Pages (July 2013)

Volume 19, Issue 2, Pages (February 2018)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 371, Issue 9618, Pages (March 2008)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 18, Issue 10, Pages (October 2017)

Volume 376, Issue 9747, Pages (October 2010)

Volume 12, Issue 1, Pages (January 2011)

Volume 20, Issue 5, Pages (May 2019)

Volume 14, Issue 7, Pages (June 2013)

Presentation transcript:

Volume 11, Issue 3, Pages 266-274 (March 2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) Prof John MS Bartlett, PhD, Alison F Munro, MSc, Janet A Dunn, PhD, Christopher McConkey, MSc, Sarah Jordan, MSc, Prof Chris J Twelves, MD, Prof David A Cameron, MD, Jeremy Thomas, MBBS, Fiona M Campbell, MSc, Daniel W Rea, PhD, Elena Provenzano, MBBS, Prof Carlos Caldas, FMedSci, Paul Pharoah, BMBCh, Louise Hiller, PhD, Helena Earl, MBBS, Prof Christopher J Poole, MBBChir The Lancet Oncology Volume 11, Issue 3, Pages 266-274 (March 2010) DOI: 10.1016/S1470-2045(10)70006-1 Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 1 Hazard ratio (HR) plot for treatment-by-marker interactions for relapse-free survival Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil. The Lancet Oncology 2010 11, 266-274DOI: (10.1016/S1470-2045(10)70006-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 2 Hazard ratio (HR) plot for treatment-by-marker interactions for overall survival Ch17CEP=chromosome 17 centromere enumeration probe. IHC=immunohistochemistry. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil. The Lancet Oncology 2010 11, 266-274DOI: (10.1016/S1470-2045(10)70006-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 3 Relapse-free and overall survival for patients with tumours exhibiting Ch17CEP duplication and Ch17CEP normal (A) Relapse-free survival for ChCEP17 normal. (B) Relapse-free survival for ChCEP17 duplication. (C) Overall survival for ChCEP17 normal. (D) Overall survival for ChCEP17 duplication. Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil. The Lancet Oncology 2010 11, 266-274DOI: (10.1016/S1470-2045(10)70006-1) Copyright © 2010 Elsevier Ltd Terms and Conditions

Figure 4 Hazard ratio (HR) plot for treatment by marker interactions for relapse-free survival stratified by Ch17CEP and HER2/TOP2A Ch17CEP=chromosome 17 centromere enumeration probe. ECMF=epirubicin, cyclophosphamide, methotrexate, fluorouracil. CMF=cyclophosphamide, methotrexate, fluorouracil. The Lancet Oncology 2010 11, 266-274DOI: (10.1016/S1470-2045(10)70006-1) Copyright © 2010 Elsevier Ltd Terms and Conditions